Olmesartan in crisis? Removal of discussion event schedule

The destiny of olmesartan – whose safety letter is distributed in Korea as removed from the insurance benefit by the French Agency for the Safety of Health Products(ANSM) due to suspicion in safety and validity – is expected to be decided soon.

The Ministry of Food and Drug Safety will hold the Central Pharmacists Deliberation Committee(hereinafter referring to CPDC) to review modification of ...